Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01324310
Recruitment Status : Completed
First Posted : March 29, 2011
Results First Posted : May 15, 2013
Last Update Posted : May 4, 2016
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation

Brief Summary:
The purpose of this study is to evaluate the effect and safety of multiple doses of ketoconazole on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

Condition or disease Intervention/treatment Phase
Hematologic Malignancy Malignant Lymphoma Drug: Romidepsin Drug: Ketoconazole Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Ketoconazole on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer
Study Start Date : April 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Romidepsin and ketoconazole

Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.

Ketoconazole 400 mg oral once daily on Days 4-8

Drug: Romidepsin
Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
Other Name: Istodax®, Romi, ROMI

Drug: Ketoconazole
Ketoconazole 400 mg oral once daily on Days 4-8




Primary Outcome Measures :
  1. Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin [ Time Frame: Days 1 and 8; at 0 (pre-dose) 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    AUC0-t: area under the plasma concentration time-curve from Time 0 to the time of the last quantifiable concentration (Ct), calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing. For AUC0-t, an analysis of variance (ANOVA) model was used to estimate the ratio of geometric means and its 90% CI between romidepsin alone and romidepsin in the presence to ketoconazole.

  2. Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC 0-24) [ Time Frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion ]
    AUC 0-24: area under the plasma concentration time-curve from Time 0 to 24 hours, calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing; for AUC 0-24 an analysis of variance (ANOVA) model was used to estimate the ratio of geometric means and its 90% confidence interval (CI) between romidepsin alone and romidepsin in the presence of ketoconazole

  3. Area Under the Plasma Concentration Time-curve From Time 0 Extrapolated to Infinity (AUC0-∞) [ Time Frame: Days 1 and 8; at 0 (pre-dose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    AUC0-∞: area under the plasma concentration time-curve from Time 0 extrapolated to infinity, calculated as [AUCt + Ct/λz].

  4. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Days 1 and 8; at 0 (pre-dose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    Cmax: maximum observed plasma concentration, obtained directly from the observed concentration versus time data; for Cmax, an analysis of variance (ANOVA) model was used to estimate the ratio of geometric means and its 90% confidence interval (CI) between romidepsin alone and romidepsin in the presence of ketoconazole

  5. Time to Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Days 1 and 8; at 0 (pre-dose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    Tmax: time to maximum observed Tmax, obtained directly from the observed concentration versus time data

  6. Estimate of the Terminal Elimination Half-life in Plasma (t1/2) [ Time Frame: Days 1 and 8; at 0 (pre-dose),1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    Terminal elimination half-life (t1/2) in plasma, was calculated as [(ln 2)/λz]

  7. Apparent Total Plasma Clearance (CL) [ Time Frame: Days 1 and 8; at 0 (pre-dose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    Apparent total plasma clearance, (CL) calculated as [Dose/AUC 0-∞].

  8. Apparent Total Volume of Distribution (Vz) [ Time Frame: Days 1 and 8, At 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion. ]
    Vz: apparent total volume of distribution, calculated as [(CL)/λz].


Secondary Outcome Measures :
  1. Summary of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Day 1 up to Day 36 (28 days after last treatment) ]
    All 15 subjects in the safety population received at least 1 dose of romidepsin. AEs were considered related if assessed by the Investigator as possibly, probably or definitely related to study drug. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females 18 years of age or older at the time of signing the informed consent document.
  2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Must have diagnosis of advanced malignancy and must have failed other available therapies considered standard of care for their disease.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  6. Negative urine or serum pregnancy test on females of childbearing potential; and
  7. All females of childbearing potential must use an effective barrier method of contraception (either an intrauterine contraceptive device [IUCD] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter. Female subjects should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives. An in vitro binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors.

Exclusion Criteria:

  1. Any significant medical condition or psychiatric illness that would prevent the subject from participating in the study.
  2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Subjects with significant gastrointestinal disease that may impair drug absorption, such as subjects with a history of Cohn's disease, colectomy, gastrectomy, celiac disease, or other diseases with known malabsorption.
  4. Serum potassium < 3.8 mmol/L or serum magnesium < 0.85 mmol/L (magnesium converts to 2.1 mg/dl or 1.7 mEq/L) (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria).
  5. Concomitant use of drugs that may cause a significant prolongation of the corrected measurement of the time between the start of the cardiac Q wave and the end of the T wave (QTc).
  6. Concomitant use of Cytochrome P 450 3A4 (CYP3A4) strong inhibitors within 1 week of trial medications.
  7. Concomitant use of CYP3A4 strong inducers within 2 weeks of trial medications.
  8. Concomitant use of therapeutic warfarin due to a potential drug interaction. Use of a low dose of warfarin or another anticoagulant to maintain patency of venous access port and cannulas is permitted.
  9. Clinically significant active infection.
  10. Known infection with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C.
  11. Inadequate bone marrow or other organ function as evidenced by:

    • Hemoglobin < 9 g/dL (transfusions and/or erythropoietin are permitted);
    • Absolute neutrophil count (ANC) ≤ 1.0 * 10^9 cells/L [subjects with neutropenia (ANC 1-1.5) as a function of their disease may be supported with granulocyte-colony stimulating factor (G-CSF)];
    • Platelet count < 100 * 10^9 cells/L or platelet count < 75 * 10^9 cells/L if bone marrow disease involvement is documented;
    • Total bilirubin > 1.5 * upper limit of normal (ULN) or > 2.0 * ULN in the presence of demonstrable liver metastases;
    • Serum aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) > 1.5 * ULN or > 2.0 * ULN in the presence of demonstrable liver metastases; or
    • Serum creatinine > 2.0 * ULN;
  12. Prior chemotherapy treatment within 3 weeks prior to the first day of romidepsin treatment (6 weeks for nitrosoureas) or prior treatment with an investigational agent within 4 weeks prior to the first day of romidepsin treatment.
  13. Prior radiotherapy within 4 weeks prior to the first day of treatment. Subjects who have not fully recovered or whose acute toxicity related to prior radiotherapy has not returned to baseline are ineligible.
  14. Major surgery within 2 weeks of study entry (day 1).
  15. Concomitant use of any other anti-cancer therapy.
  16. Concomitant use of any investigational agent.
  17. Prior exposure to romidepsin (other histone deacetylase[HDAC] inhibitors are allowed).
  18. Any known cardiac abnormalities, such as:

    • Congenital long measure of the time between the start of the Q wave and the end of the T wave (QT) syndrome;
    • . Mean QTc formula (QTcF) interval > 450 msec;
    • A myocardial infarction within 12 months of study entry;
    • A history of coronary artery disease (CAD), e.g., angina Canadian Class II-IV. A stress imaging study should be performed for any subject whose cardiac status is uncertain. If abnormal, an angiography should be completed to define whether or not CAD is present.
    • An electrocardiogram (ECG) recorded at screening showing evidence of cardiac ischemia (ST depression of ≥ 2 mm, measured from isoelectric line to ST segment). A stress imaging study should be performed for any subject whose cardiac status is uncertain. If abnormal, an angiography should be completed to define whether or not CAD is present.
    • Congestive Heart Failure (CHF) that meets the New York Heart Association (NYHA) Class II to IV definitions (see Appendix F) and/or ejection fraction < 40% by multi gated acquisition (MUGA) scan or < 50% by echocardiogram and/or magnetic resonance imaging (MRI);
    • A known history of sustained ventricular tachycardia(VT), ventricular fibrillation (VF), torsades de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
    • Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above);
    • Uncontrolled hypertension, i.e., blood pressure (BP) of ≥ 160/95; or
    • Any cardiac arrhythmia requiring anti-arrhythmic medication
  19. Subjects who are pregnant or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01324310


Locations
Layout table for location information
United States, Florida
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United Kingdom
Sarah Cannon Research UK
London, United Kingdom, W1G6AD
Sponsors and Collaborators
Celgene Corporation
Investigators
Layout table for investigator information
Study Director: Ken Takeshita, MD Celgene Corporation

Layout table for additonal information
Responsible Party: Celgene Corporation
ClinicalTrials.gov Identifier: NCT01324310     History of Changes
Other Study ID Numbers: ROMI-ADVM-001
2010-022144-20 ( EudraCT Number )
First Posted: March 29, 2011    Key Record Dates
Results First Posted: May 15, 2013
Last Update Posted: May 4, 2016
Last Verified: March 2016

Keywords provided by Celgene Corporation:
ROMI-001
romi
Romidepsin
Istodax
advanced malignancy
PK
pharmacokinetics

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Ketoconazole
Romidepsin
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Antibiotics, Antineoplastic
Antineoplastic Agents